KROS · Keros Therapeutics Inc
United States · RS rating 46 · As of 2026-11-03
| Price | 10.83 USD |
|---|---|
| 1-day change | +0.7% |
| RS rating (overall / 1M / 3M / 12M) | 46 / 43 / 80 / 32 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 19 / 24 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -377.8% |
| Sales growth Q/Q | -97.3% |
| Distance from 52-week high | +50.4% |
| Market cap (USD) | $228.7M |